Compare · NAGE vs RLX
NAGE vs RLX
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.05B, about 11.4x NAGE ($268.4M).
- Over the past year, NAGE is down 74.8% and RLX is down 10.4% - RLX leads by 64.4 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- RLX has more recent analyst coverage (2 ratings vs 1 for NAGE).
PerformanceNAGE-74.83%RLX-10.41%
2025-06-09+0.00%2026-06-08
- Company
- Niagen Bioscience Inc.
- RLX Technology Inc.
- Price
- $3.38-1.89%
- $1.98-0.75%
- Market cap
- $268.4M
- $3.05B
- 1M return
- -19.24%
- -7.91%
- 1Y return
- -74.83%
- -10.41%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 2
- Recent ratings
- 1
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest NAGE
- Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience Announces Participation in Upcoming Investor Conferences
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
- SEC Form DEFA14A filed by Niagen Bioscience Inc.
- SEC Form DEF 14A filed by Niagen Bioscience Inc.
- Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao